Cleveland Clinic London Cancer Centre will expand an 81,000-square-foot at 40 Grosvenor Place in Belgravia, London, to provide medical oncology and haematology care, as well as systemic cancer therapies such as immunotherapy, chemotherapy, targeted therapies, and radiotherapy.

Construction is scheduled to commence in the fourth quarter of 2025, with completion expected by the end of 2027.
The Cleveland Clinic London Cancer Centre site, which offers one of the most extensive cancer programs in the UK Independent market, will provide the most advanced treatments. Multidisciplinary cancer care will comprise surgical oncology, medical oncology, and haematology, as well as systemic cancer medicines like immunotherapy, chemotherapy, targeted therapies, and radiotherapy that are personalised to each patient. In addition to cancer care, Cleveland Clinic London wants to expand its clinical offerings in the future.
“Our mission is rooted in providing patients with the highest quality care, wherever they live,” said Tom Mihaljevic, M.D., Cleveland Clinic CEO and President and holder of the Morton L. Mandel CEO Chair. “By expanding our services in London, we are addressing the growing demand for advanced cancer care and meeting the needs of patients closer to home.”
